GlaxoSmithKline chops up mature drugs portfolio for $3B sale

GlaxoSmithKline ($GSK) may be hitting obstacles all over the world, what with bribery fines and probes, Advair rivals in Europe, and the like. But the U.K. drugmaker has managed to make progress on its plan to offload some of its older products: It's planning to sell off chunks of the portfolio in geographic areas, with Denmark's Lundbeck and India's Lupin are said to be in the running for regional pieces, likely in the U.S. Report